Amalgamated Financial’s BioAtla BCAB Stock Holding History

Amalgamated Financial’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$13K	Buy	+51	New	+$21.3K	﹤0.01%	2845

Other funds holding BCAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Amalgamated Financial's BCAB Position: Q1 2022 in Review

Amalgamated Financial opened a new position in BioAtla (BCAB) in Q1 2022: 51 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #2845 among its holdings.

97 funds tracked by Wall St. Rank hold BCAB as of Q1 2022.

Amalgamated Financial held 51 shares of BioAtla worth $13K as of Q1 2022.
BioAtla was a new Amalgamated Financial position in Q1 2022.
BioAtla made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2845 holding.
97 funds tracked by Wall St. Rank held BioAtla as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.